Aust. Radiol. (1975). 19,72
Patient Radiation Doses From Radiopharmaceuticals A. C. MCEWAN,BSc. (Hons.), Ph.D. INTRODUCTION Tables of absorbed doses to patient organs arising from radiopharmaceutical procedures have been compiled by Hine and Johnston ( 1970) and the International Commission on Radiological Protection ( ICRP, 1971 1. The latter publication lists references to sources from which the data have been obtained and includes absorbed dose calculations performed in conjunction with a survey of radionuclide use in New Zealand in 1966 (McEwan, 1967, I971 ). Many of the references, however, provide little or no information on physiological data and there is considerable variation in the adequacy of the calculations, In conjunction with a further survey of radiopharmaceutical use in New Zealand in 1973 CakUhtiOnS Of Patient organ doses have been revised and extended ( a ) to take advantage of improved data and methods of computation now available, notably in publications of the Medical Internal Radiation Dose Committee (MIRD) of the US. Society of Nuclear Medicine, ( b ) to take account of more recently published biological data, and (c) to include a number of radiopharmaceuticals which have come into widespread use over the last few years. Dose estimates have been obtained for organs receiving the highest doses and €or the gonads, so that h e data may be used for estimates of genetic dose. All radiopharmaceuticals in routine use in New Zealand in 1973 are included.
METHOD OF DOSE CALCULATION Organ doses have been calculated using the absorbed fraction approach (Ellett, Callahan and Brownell, 1964) according to the expression t i sfi>?p ,
Patient Radiation Doses From Radiopharmaceuticals A. C. MCEWAN,BSc. (Hons.), Ph.D. INTRODUCTION Tables of absorbed doses to patient organs arising from radiopharmaceutical procedures have been compiled by Hine and Johnston ( 1970) and the International Commission on Radiological Protection ( ICRP, 1971 1. The latter publication lists references to sources from which the data have been obtained and includes absorbed dose calculations performed in conjunction with a survey of radionuclide use in New Zealand in 1966 (McEwan, 1967, I971 ). Many of the references, however, provide little or no information on physiological data and there is considerable variation in the adequacy of the calculations, In conjunction with a further survey of radiopharmaceutical use in New Zealand in 1973 CakUhtiOnS Of Patient organ doses have been revised and extended ( a ) to take advantage of improved data and methods of computation now available, notably in publications of the Medical Internal Radiation Dose Committee (MIRD) of the US. Society of Nuclear Medicine, ( b ) to take account of more recently published biological data, and (c) to include a number of radiopharmaceuticals which have come into widespread use over the last few years. Dose estimates have been obtained for organs receiving the highest doses and €or the gonads, so that h e data may be used for estimates of genetic dose. All radiopharmaceuticals in routine use in New Zealand in 1973 are included.
METHOD OF DOSE CALCULATION Organ doses have been calculated using the absorbed fraction approach (Ellett, Callahan and Brownell, 1964) according to the expression t i sfi>?p ,
